Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The proposed study focuses on testing a novel adapted evidence-based multilevel intervention, Deprescribing Thyroid Hormone In Older Adults (D-THIO), to support thyroid hormone deprescribing (dose de-escalation and/or discontinuation) in older adults with thyroid hormone overtreatment and/or misuse and reduce patient harm. Findings from this study will lay the groundwork for broad implementation of D-THIO and serve as a model for deprescribing inappropriate medications for other endocrine conditions and conditions with biochemical monitoring.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• age 65 years and older

• on thyroid hormone therapy and have a serum Thyroid-stimulating hormone (TSH) \<0.5 mIU/L or are on thyroid hormone therapy for an inappropriate indication

• English speaking

• without cognitive impairment

Locations
United States
California
University of California San Francisco
RECRUITING
San Francisco
Michigan
University of Michigan
RECRUITING
Ann Arbor
Henry Ford Health System
RECRUITING
Detroit
Contact Information
Primary
Brittany Gay
bbartol@umich.edu
734-763-8608
Time Frame
Start Date: 2024-12-02
Estimated Completion Date: 2029-04
Participants
Target number of participants: 900
Treatments
Experimental: D-THIO (Deprescribing Thyroid Hormone In Older Adults)
D-THIO is an innovative adapted multilevel intervention.~Providers in the intervention arm will receive: 1) an introductory letter, and 2) the D-THIO pharmaceutical opinion via EMR-compatible correspondence.~After randomization of their treating providers, patients in the intervention arm will receive a study packet including: 1) introductory letter, and 2) the D-THIO patient brochure (educational EMPOWER brochure).
Active_comparator: Enhanced usual care
This arm will receive enhanced usual care.~Providers in the control arm will receive: 1) an introductory letter signed by the PI and site-PIs, and 2) the ATA hypothyroidism pocket card via EMR.~Patients in the control arm will receive a study packet including: 1) introductory letter, and 2) the ATA patient brochure.
Related Therapeutic Areas
Sponsors
Leads: University of Michigan
Collaborators: National Institute on Aging (NIA)

This content was sourced from clinicaltrials.gov